在临床实践中改善心力衰竭患者的管理,减少排泄分数:对 ангиотензин受体-内利素抑制剂的案例
Massimo Iacoviello1, Filippo Maria Sarullo2, Claudio Bilato3
1Department of Medical and Surgical Sciences, University of Foggia Foggia, Italy.
Cardiac failure review
|July 31, 2025
概括
以指导方针为导向的医疗治疗,包括血管激素受体-尼普利辛抑制剂,对于心力衰竭与减少射出分数 (HFrEF) 至关重要. 本文探讨了实施该计划的障碍.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 减少喷射分数 (HFrEF) 的心力衰竭具有高风险的不良结果.
- 以指导方针为导向的医疗治疗对于降低HFrEF患者的发病率和死亡率至关重要.
研究的目的:
- 调查HFrEF疗法的"四大支柱"在现实世界中实施的障碍.
- 为改善HFrEF中指南导向医疗疗的采用提供指导.
主要方法:
- 目前欧洲心脏病学会对HFrEF的2021年指导方针的审查.
- 对关键HFrEF药物的现实应用挑战的分析.
- 识别阻碍最佳治疗启动和定位的障碍.
主要成果:
- ангиотензин受体-neprilysin抑制剂为HFrEF患者提供了显著的益处.
- 针对HFrEF的指南导向医疗疗的现实应用仍然不够理想.
- "四大支柱"的一致使用和快速定位存在障碍.
结论:
- "四大支柱"的早期启动和定位 (血管激素受体-尼普利辛抑制剂,β-阻断剂,SGLT2抑制剂,MRAs) 对于HFrEF管理至关重要.
- 解决实施障碍是必要的,以改善HFrEF患者的治疗结果.
- 需要指导,以提高HFrEF指导方针在不同患者个人资料的实际应用.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25
Heart Failure II: Pathophysiology
44
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
44
Heart Failure VII: Nursing Interventions
140
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
140
Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435
Heart Failure Drugs: Diuretics
495
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
495


